Europe
Event sees new Memorandum of Understanding signed by PROLMED and KPTA.
Apogenix announced that a new publication in Human Vaccines & Immunotherapeutics highlights the advantages of hexavalent CD40 agonists, such as HERA-CD40L, in the targeting of CD40 in immuno-oncology.
Helsinn and Recordati Rare Diseases announce that a co-sponsored Symposium, organized by the two companies at the European Society for Dermatological Research Annual Meeting, , will provide a better knowledge of Chlormethine Gel’s mode of action as well as guidance on the management of the Chlormethine gel induced dermatitis.
Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of products and services leveraging its proprietary biomedicine technology platform Dataome, is due to participate in several upcoming conferences between September and December, 2019.
MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, is pleased to announce that it will host a scientific lunch symposium titled “Local Therapies in Malignant Gliomas - update and new perspectives” during the 19th European Congress of Neurosurgery in Dublin, Ireland.
Heidelberg Pharma AG announced that its subsidiary Heidelberg Pharma Research GmbH will receive a research grant from the European Union.
Toujeo® improved blood sugar control vs insulin degludec in adults with type 2 diabetes and moderate-to-severe kidney impairment • Secondary analyses expand results from BRIGHT head-to-head clinical trial
Data to be presented at inaugural STORM Therapeutics RNA Epigenetics in Human Disease Conference in Cambridge, UK
The Janssen Pharmaceutical Companies of Johnson & Johnson announced multiple data presentations from its solid tumour portfolio, including key prostate cancer data, will be featured at the European Society for Medical Oncology 2019 Annual Congress, taking place 27th September to 1st October in Barcelona, Spain.
Company’s insulin-based Imotope™ IMCY-0098 shows excellent safety profile and promising clinical trends
PRESS RELEASES